Research design, sufferers, remedy and oversight
A section 1, multi-center, open-label, first-in-human trial of ELI-002 2P monotherapy was performed in 5 ascending dose cohorts at seven facilities in the US between 4 October 2021 and 6 September 2023 (the medical cutoff date for the outcomes introduced right here). A set dose of Amph-Peptides 2P (G12D and G12R, 0.7 mg every) was administered with escalating doses of 0.1, 0.5, 2.5, 5.0 and 10.0 mg of Amph-CpG-7909 adjuvant. Eligible sufferers had been 18 years of age or older, had mKRAS G12D-mutated or G12R-mutated pancreatic or colorectal cancers and had been at excessive danger for relapse due to the presence of MRD (indicated by ctDNA positivity or elevated serum CA19-9 and/or CEA). Tutorial facilities entered medical information into Medidata RAVE 2018.2.4. Further particulars are supplied within the research protocol (Supplementary Knowledge 1).
Two collaborating establishments, the College of Colorado College of Medication and Metropolis of Hope, had the research permitted by WIRB Copernicus (WCG IRB). Six different collaborating establishments had the research permitted by their native IRBs: Memorial Sloan Kettering Most cancers Heart (MSKCC IRB), The College of Texas MD Anderson (College of Texas MD Anderson Workplace of Human Topic Safety), the College of Iowa (College of Iowa Human Topics Workplace/IRB), Northwell Well being (Feinstein Institutes for Medical Analysis, Northwell Well being IRB), the College of California, Los Angeles (UCLA Workplace of the Human Analysis Safety Program) and Massachusetts Common Hospital (Dana-Farber Most cancers Institute Workplace for Human Analysis Research). The research was permitted by the US Meals and Drug Administration (FDA) and registered on ClinicalTrials.gov (NCT04853017).
Sufferers
We enrolled grownup (≥18 years of age) sufferers with Jap Cooperative Oncology Group (ECOG) efficiency standing (PS) of 0 or 1 with pathologically confirmed mKRAS (G12D or G12R) PDAC or CRC who had been MRD+ with both (1) absolute CA19-9 ≥ 90 U ml−1 or CEA ≥ 15 ng ml−1 or (2) successively rising values (≥1 week aside) in both CA19-9 or CEA not attributable to a non-cancer situation, equivalent to pancreatitis, peritonitis, postoperative leak/fistula or biliary obstruction. Sufferers had recovered from prior surgical procedure, chemotherapy or radiation with out ongoing medical/surgical points and had been keen to make use of efficient strategies to keep away from being pregnant and supplied written knowledgeable consent. Baseline absolute neutrophil depend ≥1.5 × 109/L, platelets ≥100 × 109/L, regular vary liver perform assessments, serum creatinine <1.5 (or if serum creatinine was ≥1.5 mg dl−1, creatinine clearance calculated by the Cockcroft–Gault system ≥60 ml min−1 was acceptable), albumin ≥2.5 g dl−1 and IL-6 < 500 pg ml−1 had been required.
Sufferers with PDAC had high-risk tumor phases I or II or III or oligometastatic stage IV illness per present American Joint Committee on Most cancers (AJCC) standards with no proof of illness on present imaging (equivocal radiographic findings, equivalent to subcentimeter lesions or potential resolving delicate tissue modifications after surgical procedure, had been accepted), prior remedy with customary chemotherapy/chemoradiation administered within the neoadjuvant and/or adjuvant setting and full tumor resection (R0 or R1 pathologic margins), with focal use of intraoperative irreversible electroporation permitted.
Sufferers with CRC had high-risk stage II (T4N0), stage III (T4N1-2/TanyN2) or stage IV oligometastatic illness per present AJCC staging standards, prior cytotoxic chemotherapy administered within the neoadjuvant or adjuvant setting, or as complete neoadjuvant remedy, and full surgical resection (R0 or R1 pathologic margins), with focal use of intraoperative irreversible electroporation permitted.
We excluded sufferers who had obtained anti-tumor remedy inside 4 weeks; who had a historical past of mind metastasis; who had different malignancies throughout the previous 3 years (aside from adequately handled carcinoma of the cervix, bladder or prostate or basal or squamous cell pores and skin most cancers); who had been receiving immunosuppressive medication; who had severe comorbid sicknesses, together with uncontrolled an infection, class III or class IV (New York Coronary heart Affiliation) cardiac failure, myocardial infarction inside 6 months, lively seizure problems, autoimmune illnesses or interstitial lung illness if requiring systemic steroids; who had pulse oximetry lower than 92% on room air; who had prior organ transplants; and who had HIV/AIDS, hepatitis B or hepatitis C (except they’d a sustained virologic response to direct-acting antiviral remedy), and those that had been within the first 2 weeks of SARS-CoV-2. Ladies had been excluded if pregnant or lactating. Sufferers with PDAC had been excluded when tumors had been of neuroendocrine subtype or when there was a germline BRCA 1/2 mutation. Sufferers with CRC had been excluded when tumors had been mismatch restore faulty (MSI+).
Remedy was divided right into a Prime Immunization collection (six subcutaneous doses of ELI-002 2P over 8 weeks), a 3-month No Dosing Interval (remark) and a Booster Immunization collection (4 weekly doses of ELI-002 2P). A Observe-up Interval included as much as 2 years after the primary dose of ELI-002 2P to observe security and efficacy (Prolonged Knowledge Fig. 1).
The research was sponsored and designed by Elicio Therapeutics in collaboration with the educational authors. The research and analyses had been performed in accordance with the overall ideas of the Declaration of Helsinki and Good Scientific Observe tips of the Worldwide Council for Harmonization. The trial protocol, amendments and supporting paperwork had been permitted by the native/central IRB for every research website and the US FDA and had been registered on ClinicalTrials.gov (NCT04853017). All sufferers supplied written knowledgeable consent.
A security and monitoring committee was convened to assessment security and decide dose escalation and cohort growth choices. Cohorts ranged from three to 6 sufferers with expansions allowed after the primary three sufferers accomplished 28 d with out DLT and when further eligible sufferers had been recognized.
All authors affirm that the trial was performed in accordance with the research protocol and vouch for the accuracy and completeness of the information. Knowledgeable medical author funded by the sponsor aided in preparation of the primary draft of the manuscript in accordance with Good Publication Observe tips. All authors reviewed and revised the manuscript and made the choice to submit it for publication.
The preliminary protocol (model 1.0) was permitted on 13 July 2020. Key protocol amendments are as follows. Modification 2 (model 3.0) was permitted on 23 February 2021 and included modifications requested by the FDA. This was the preliminary protocol for research initiation. On 8 April 2022, Modification 4 (model 5.0) was permitted and added serum tumor biomarkers (that’s, CEA and CA19-9) to the MRD eligibility together with ctDNA. Modification 5 (model 6.0), permitted on 2 August 2022, added language relating to pseudo-progression and continued ELI-002 dosing. Modification 6 (model 7.0) was permitted on 25 January 2023 and added language for public document seek for OS.
Endpoints and assessments
Major endpoints of the research had been security (opposed occasions had been graded per Frequent Terminology Standards for Antagonistic Occasions, model 5.0), tolerability and willpower of the RP2D. The secondary endpoint was tumor biomarker discount and clearance outlined by means of evaluation of ctDNA and/or serum tumor antigens (CA19-9 or CEA), and exploratory endpoints included radiographic RFS and immunogenicity. RFS and tumor biomarker endpoints had been correlated with T cell biomarkers and high-resolution HLA typing.
Immunogenicity evaluation
PBMCs for immunogenicity evaluation had been processed from leukapheresis (baseline and week 9) or entire blood collections (all different timepoints). Affected person PBMCs had been processed by Ficoll-Hypaque gradient protocol for leukapheresis samples or cell processing tubes (BD Biosciences) for entire blood samples. PBMCs had been resuspended in CS10 freezing media (Cryostor), frozen in aliquots of 10–20 million cells per cryovial and saved in a temperature-monitored liquid nitrogen vapor section freezer.
Ex vivo FluoroSpot assay
A direct IFNγ/GrB FluoroSpot assay was carried out on thawed PBMCs. Cryopreserved PBMCs had been thawed in 10% human AB serum/RPMI media + Benzonase and rested in a single day at 37 °C. Pre-coated human IFNγ/GrB FluoroSpot plates had been washed with PBS and blocked with AIM-V media for not less than 30 min (MabTech). Then, 2 × 105 rested PBMCs had been plated into every effectively and stimulated for 44 h as per the producer’s directions with seven particular person mKRAS peptide swimming pools and a WT peptide pool (swimming pools consisted of KRAS 18-mer peptide and 9-mer and 10-mer overlapping peptides (OLPs) of every KRAS 18mer; Supplementary Desk 1) at 2 µg/peptide/ml. No exogenous cytokines had been added to the PBMCs throughout this assay. All samples had been plated in triplicate. Dimethyl sulfoxide was used because the destructive management (background wells), and anti-CD3 (MabTech) was used because the optimistic management. The plate was developed primarily based on the producer’s directions. Plates had been scanned and counted utilizing the IRIS plate reader (MabTech) utilizing FITC and Cy3 filters (Supplementary Fig. 2). Knowledge are background subtracted, averaged per triplicate measurements and normalized to 1 × 106 PBMCs. A responder within the FluoroSpot assay was outlined as a affected person having ≥2-fold enhance from baseline at any post-vaccination timepoint and greater than 50 SFCs/1 × 106 PBMCs. Baseline mKRAS-specific T cell responses had been outlined as greater than 50 SFCs/1 × 106 PBMCs to any mKRAS antigen within the FluoroSpot assay. The above ex vivo IFNγ/GrB FluoroSpot assay was additionally used to check T cell responses to infectious illness antigens. Baseline PBMCs had been stimulated with 2 µg/peptide/ml of the next antigen swimming pools from JPT Peptide Applied sciences: PepMix SARS-CoV-2 (S-RBD OLP pool); PepMix Pan-CMV Choose (pool of 99 peptides, outlined HLA class I- and II-restricted T cell epitopes from chosen proteins of CMV); PepMix HCMVA pp65 (pp65 OLP pool); CEFS Extremely SuperStim Pool MHC-II subset (optimistic management pool of 68 identified peptide epitopes for a broad vary of HLA subtypes and completely different infectious brokers for T cell stimulation of populations with a various ethnic background); CEFT pool (optimistic management pool of 27 peptides chosen from outlined HLA class-I restricted T cell epitopes from CMV, EBV, influenza and tetanus); PepMix Pan-EBV Choose (virus-specific pool of 135 peptides (outlined HLA class I- and II-restricted T cell epitopes) from chosen proteins of EBV); and CEFX Extremely SuperStim Pool (optimistic management pool of 176 identified peptide epitopes for a broad vary of HLA subtypes and completely different infectious brokers for T cell stimulation of populations with a various ethnic background).
Ex vivo intracellular cytokine staining
A direct ICS assay for IL2, IFNγ and TNFα was carried out by movement cytometry. PBMCs had been thawed and rested in a single day. Then, 106 PBMCs per effectively had been plated and stimulated for 17 h at 37 °C with particular person mKRAS peptide swimming pools at 2 μg/ml/peptide (Supplementary Desk 1). GolgiStop and GolgiPlug (BD Biosciences) had been additionally added to every effectively. The subsequent day, cells had been floor stained with antibodies towards CD4 (BV421, clone: SK3, BD Biosciences cat. no. 566907, 1:40), CD8 (BV786, clone: RPA-T8, BD Biosciences cat. no. 563823, 1:25), CD45RA (Alexa 700, clone: HI100, BioLegend cat. no. 304120, 1:25), CCR7 (PE-CF594, clone: 15053, BD Biosciences cat. no. 562381, 1:12.5), Aqua Stay/Lifeless marker (Thermo Fisher Scientific cat. no. L34966, 1:200) and dump markers CD14 (PE-Cy5, clone: 61D3, Thermo Fisher Scientific cat. no. 15-0149-42, 1:200), CD16 (PE-Cy5, clone: 3G8, BioLegend cat. no. 302010, 1:200) and CD19 (PE-Cy5, clone: SJ25C1, BioLegend cat. no. 363042, 1:200). Cells had been subsequently mounted with CytoFix/CytoPerm (BD Biosciences) and additional stained with antibodies towards CD3 (APC-H7, clone: SK7, BD Biosciences cat. no. 560176, 1:40), IFNγ (FITC, clone: Mab11, BioLegend cat. no. 506504, 1:200), TNFα (BV711, clone: B27, BioLegend cat. no. 502940, 1:50) and IL2 (BV650, clone: MQ1-17H12, BioLegend cat. no. 502940, 1:50). Cells mounted in 0.5% formaldehyde had been acquired on a BD FACSymphony, and information had been analyzed with BD Biosciences FlowJo model 10 software program (gating development and instance plots in Supplementary Fig. 2). A responder within the ICS assay was outlined as a affected person having ≥2-fold enhance from baseline at any post-vaccination timepoint and greater than 0.1% cytokine optimistic.
Tumor biomarker evaluation and mutation identification
Complete Genomic Profiling–Complete-Exome Sequencing was carried out to find out whether or not the affected person’s tumor harbored not less than one of many two mKRAS alleles focused by the ELI-002 2P (G12D or G12R). The Natera Signatera ctDNA take a look at evaluated for the presence or absence of ctDNA. Complete-exome sequencing was carried out on formalin-fixed, paraffin-embedded tumor samples with not less than 20% tumor content material confirmed by a pathologist below Central Lab Enchancment Amendments (CLIA) and School of American Pathologists (CAP) tips. Genomic DNA was extracted from the affected person’s regular (entire blood) and tumor tissue. Libraries of tumor and matched germline DNA had been ready, and exomic areas had been captured. The assay was carried out by goal enrichments of the remoted DNA, adopted by 440× protection sequencing on a HiSeq 2500 or a NovaSeq 6000 (Illumina). Somatic single-nucleotide variants (SNVs) that had been current within the tumor and absent within the germline had been recognized. A proprietary Natera algorithm chosen a set of 16 SNVs to maximise the detectability of tumor DNA if current in plasma. Polymerase chain response (PCR) primers focusing on the 16 personalised SNVs had been designed and synthesized for use to establish and observe ctDNA in a affected person’s plasma. Cell-free DNA was extracted from plasma and run within the multiplexed personalised PCR assay. Plasma samples with two or extra SNVs detected above a predefined confidence threshold had been deemed ctDNA optimistic, and ctDNA focus was reported as imply tumor molecules per milliliter of plasma. In sufferers who didn’t have ample tumor tissue, a plasma-based ctDNA assay for mKRAS variants was carried out: Sysmex SafeSEQ RAS-RAF. Cell-free DNA was remoted from plasma, and a next-generation sequencing (NGS)-based assay that evaluated Ok/NRAS to detect SNVs was carried out utilizing a NextSeq 550 (Illumina). ctDNA focus was reported as mutant molecules per variant and mutant allele frequency. Native testing was permitted if already obtainable to verify mKRAS standing. Serum tumor biomarkers, CA19-9 and CEA had been analyzed by research website native laboratories.
HLA typing
Excessive-resolution HLA class I A, B and C and HLA class II DRB1, DRB345, DQB1, DPB1, DQA1 and DPA1 typing was carried out at LabCorp utilizing entire blood. The tactic used focused NGS. HLA allele interpretation was primarily based on IMGT/HLA database model 3.35.0.
Statistical evaluation
Descriptive statistics had been used to summarize demographic, medical historical past and security information. Steady variables had been summarized utilizing imply, s.d., median, minimal worth and most worth. Categorical variables had been summarized utilizing frequency counts and percentages. Tumor biomarker discount/clearance was examined for affiliation with categorical variables, equivalent to excessive versus low T cell response, utilizing the Mann–Whitney take a look at. The Kaplan–Meier methodology was used to estimate the survival distributions. The log-rank take a look at was used to match the RFS between the excessive and low T cell responders. Graphs had been created utilizing GraphPad Prism model 9.4.
Reporting abstract
Additional info on analysis design is offered within the Nature Portfolio Reporting Abstract linked to this text.
